Alzheimer's Drug Discovery Foundation

Modulo Bio simulates the neuroimmune system to find medication candidates that target microglia cells. The organization's proprietary neuroimmune platform combines the most recent developments in stem cell biology and neuroscience with software, automation, and artificial intelligence to create novel treatments.

Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.

The University of Gothenburg, established in 1891, is a prominent non-endowment institution located in Gothenburg, Sweden. It is dedicated to societal advancement and aims to foster a sustainable world through education and research. The university engages actively in public discourse and maintains ongoing dialogues with the surrounding community, both nationally and internationally. It encompasses various faculties, including the School of Business, Economics and Law, which contributes to its diverse academic offerings. Through its commitment to knowledge exchange, the University of Gothenburg plays a vital role in addressing contemporary challenges and promoting innovation in society.

GLX Analytix is a biotechnology company focused on transforming healthcare through the integration of proprietary blood biomarkers and artificial intelligence. The company aims to facilitate early diagnosis and continuous monitoring of chronic diseases, thereby empowering patients to manage their health more effectively. By providing tools that enable clinicians to monitor disease progression and predict flare-ups, GLX Analytix enhances treatment plans and improves patient outcomes. As an Industrial Partner to Harvard Medical/Wyss Diagnostic Accelerator and a recipient of the Roche Future of Healthcare Award, GLX Analytix is recognized for its potential to significantly impact patient care and quality of life on a global scale.

C2N Diagnostics, LLC is a privately held company focused on the development of protein diagnostics and therapeutics targeting progressive neurodegeneration, particularly Alzheimer's disease. Founded in 2007 by Drs. David Holtzman and Randall Bateman from Washington University School of Medicine, along with LifeTech Research, the company operates from the Center for Emerging Technologies in St. Louis. C2N Diagnostics specializes in mass spectrometry-based techniques that allow for the precise identification, quantification, and monitoring of proteins and biomolecules associated with neurological disorders. By providing accurate and sensitive diagnostics, the company aims to enhance the detection and characterization of neurocognitive disorders, ultimately supporting improved patient care and treatment strategies.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

RetiSpec is a company focused on advancing early detection of Alzheimer’s Disease through its innovative non-invasive eye scanning technology. By employing AI-driven retinal imaging, RetiSpec's solution enables healthcare providers to identify neurodegenerative disease markers during a simple eye exam. This approach facilitates early diagnosis, allowing clinicians to intervene with emerging therapeutics before symptoms arise, thereby potentially impacting the progression of the disease. RetiSpec aims to make early detection accessible and affordable, contributing significantly to the management of Alzheimer's Disease.

Coya Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies that enhance the function of regulatory T cells (Tregs) in vivo. The company is advancing multiple first-in-class and best-in-class approaches, including allogeneic Treg-derived exosome therapeutics and novel biologics. Coya's proprietary medicinal products are designed to modulate Treg function, targeting a range of conditions such as neurodegenerative, autoimmune, and metabolic diseases. By harnessing the therapeutic potential of Tregs, Coya Therapeutics aims to address significant unmet medical needs in these critical areas of health.

NeuroAge Therapeutics is a biotechnology company focused on longevity and neuroscience. It develops novel pharmaceuticals to slow or reverse biological brain aging and treat neurodegenerative diseases, leveraging machine learning and an aging clock technology.

Superfluid DX is a company focused on developing advanced molecular diagnostics technology aimed at early disease detection and monitoring. By leveraging innovative research in transcriptomics, Superfluid DX analyzes tissue-specific cell-free circulating RNA found in blood samples. This non-invasive approach enables the identification of genetic information linked to neurodegenerative diseases and other conditions, providing healthcare professionals with critical insights into a patient's health status. The company's platform is designed to facilitate early diagnosis and ongoing monitoring of organ damage, ultimately improving patient outcomes by enabling timely interventions.

GliaPharm SA is a Swiss biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders. Established in 2016 and headquartered in Geneva, GliaPharm specializes in targeting glial cells, which are the support cells of neurons, to enhance brain metabolism in pathological conditions. The company utilizes its GliaX technology platform to identify drugs that influence glial cell activity and brain energy metabolism. This platform incorporates high throughput screening technologies, metabolic tests for in vitro and in vivo assessments, and various rodent models to study neurological diseases such as Alzheimer's disease, amyotrophic lateral sclerosis, and other psychiatric conditions. Through its research and development efforts, GliaPharm aims to provide healthcare providers with novel therapeutic options for patients suffering from these disorders, positioning itself as a leader in glia-mediated neuroprotection and cognitive function maintenance.

Imeka Solutions Inc., established in 2011 and based in Sherbrooke, Canada, specializes in medical image processing services. It provides advanced MRI-based techniques such as diffusion tensor imaging, tractography, and free water imaging to clients including neurologists, clinicians, and pharmaceutical researchers. Imeka's platform leverages deep learning algorithms and high-resolution MRI structures to quantify and understand brain connectivity, particularly white matter, aiding in neuroinflammation and demyelination research.

CuraSen Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company specializes in small molecule drugs that target a novel mechanism in the brain, aiming to restore function, improve symptoms, and modify the progression of conditions such as Parkinson's disease, Alzheimer's disease, and less common orphan neurodegenerative disorders. Founded in 2016, CuraSen Therapeutics is headquartered in Los Altos, California.

BrainScope, established in 2010, is a medical neurotechnology company based in Bethesda, Maryland. It specializes in developing non-invasive, hand-held medical devices to aid healthcare professionals in rapidly and accurately assessing brain injuries, particularly traumatic brain injuries and concussions. BrainScope's flagship product, BrainScope One, uses electroencephalogram (EEG) signals and advanced algorithms to objectively determine the likelihood and severity of brain injuries, enabling timely and improved patient care. The company serves military markets, emergency departments, pre-hospital/urgent care units, and sports sectors worldwide.

Aprinoia Therapeutics Inc. is a clinical-stage biotechnology company focused on advancing brain health through innovative diagnostic tools and therapies for neurodegenerative diseases. Founded in 2015 and headquartered in Taipei, Taiwan, with additional locations in China and Japan, Aprinoia develops imaging-based diagnostics, including 18F-PM-PBB3, a tau positron-emission tomography (PET) tracer that aids in the diagnosis of tauopathies. The company also manufactures an alpha-synuclein PET imaging tracer. By targeting protein aggregates associated with conditions like Alzheimer's and Parkinson's diseases, Aprinoia aims to enhance precision medicine in neuroscience and improve patient outcomes. The company's commitment to addressing the complexities of neurodegenerative diseases positions it as a leader in the development of first-in-class and best-in-class diagnostic and therapeutic solutions.

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for various brain injuries, including traumatic brain injuries, concussions, acute ischemic strokes, and neurodegenerative disorders like Alzheimer’s disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selective astrocyte activation. Its lead product, AST-004, is a novel small molecule designed for acute administration that protects and repairs damaged neurons by selectively stimulating astrocytes. Astrocyte Pharmaceuticals aims to advance innovative therapeutic agents to improve recovery and well-being for patients suffering from brain injuries.

ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, focused on developing diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers, which are unrelated to traditional markers such as ß-amyloid or tau. By employing next-generation sequencing to analyze methylcytosines in mitochondrial DNA, ADmit Therapeutics provides medical practitioners with a simplified method for detecting early-stage Alzheimer’s disease. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in the accelerated identification of potential curative drugs.

ALZpath is a biotechnology company specializing in innovative diagnostic solutions for Alzheimer's disease. It offers laboratory research services, including early-stage diagnosis through blood tests measuring pTau217 levels, and personalized treatment interventions to enhance detection and improve patient outcomes.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages groundbreaking research from the Akassoglou lab at Gladstone/UCSF, which identifies fibrin as a crucial factor in driving chronic innate immune activation associated with various diseases. By creating therapeutics that address neuroinflammation and vascular dysfunction, Therini Bio aims to provide potential treatments for conditions such as multiple sclerosis, thereby enhancing the quality of life for patients facing these challenging health issues.

Cognito Therapeutics, established in 2016 and headquartered in Newton Centre, Massachusetts, with additional locations in San Francisco and Boston, is a clinical-stage neurotechnology company. It specializes in developing non-invasive, device-based therapies to treat neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's innovative approach involves using induced brain wave oscillations to reactivate the immune system in the brain, aiming to reduce typical disease hallmarks such as amyloid plaques and tau tangles. Co-founded by MIT professors Li-Huei Tsai and Ed Boyden, Cognito's lead therapy is currently in a pivotal study for Alzheimer's, and has been recognized as a Breakthrough Device by the FDA.

ToxGenSolutions is a biotechnology company that specializes in developing diagnostic tools for preclinical diagnostics, particularly targeting Alzheimer's Disease. The company employs (epi-)genetic approaches to address molecular initiation events and key adverse outcome pathways associated with various pathologies, including neurodegeneration, cancer, and immune dysfunction. By focusing on mechanism-based genetic signatures, ToxGenSolutions aims to identify and classify new leads and toxicants during the drug screening and development process. This innovative approach enables healthcare professionals to intervene early in the disease progression, ultimately enhancing safety assessments and improving therapeutic strategies in drug development.

Imaginostics specializes in developing advanced diagnostic tools that enhance precision medicine for clinicians and drug developers. The company utilizes proprietary MRI physics-based technology, which significantly improves vascular imaging and provides quantitative measurements of vascular structure, function, and leakage. This technology is designed to work with standard MRI scanners and employs a non-toxic iron supplement for contrast, avoiding the risks associated with traditional gadolinium-based agents. Imaginostics focuses on noninvasive imaging solutions for various applications, including the diagnosis of neurological disorders, renal patient care, and acute diagnostics for conditions such as traumatic brain injury and stroke. By collaborating with leading researchers and providing biomarker solutions through contract research organizations, Imaginostics aims to accelerate drug development, enhance personalized healthcare, and contribute to the fight against aging.

Superfluid DX is a company focused on developing advanced molecular diagnostics technology aimed at early disease detection and monitoring. By leveraging innovative research in transcriptomics, Superfluid DX analyzes tissue-specific cell-free circulating RNA found in blood samples. This non-invasive approach enables the identification of genetic information linked to neurodegenerative diseases and other conditions, providing healthcare professionals with critical insights into a patient's health status. The company's platform is designed to facilitate early diagnosis and ongoing monitoring of organ damage, ultimately improving patient outcomes by enabling timely interventions.

Quanterix Corporation is a life sciences company focused on developing an ultra-sensitive digital immunoassay platform to advance precision health in diagnostics and research. Their proprietary technology, Simoa, enables the detection of protein biomarkers at very low concentrations in biological samples such as blood and serum, which are often undetectable using traditional methods. This high level of sensitivity allows for earlier disease detection, improved prognosis, and more precise treatment methods. Quanterix's platforms include bead-based and planar array systems designed to provide reliable and robust assay performance, addressing various unmet medical needs in clinical diagnostics, drug development, and life science research.

Optina Diagnostics Inc. is a Canadian company focused on developing innovative technology for the early detection of Alzheimer’s disease through hyperspectral imaging of the eye. Founded in 2010 and headquartered in Montréal, the company employs advanced retinal imaging and artificial intelligence to provide non-invasive diagnostic tests for under-diagnosed diseases. Optina Diagnostics' retinal imaging test identifies key patient features that assist healthcare professionals in evaluating health status and disease risk, enabling timely and appropriate care. The company's imaging systems not only facilitate the detection of Alzheimer's-related biomarkers, such as beta-amyloid plaques, but also address other conditions like age-related macular degeneration and diabetic retinopathy. By enhancing brain health assessment, Optina Diagnostics aims to deliver critical information early in the disease progression, ultimately improving patient outcomes.

MindImmune Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapeutic drugs that target the immune system to address diseases of the central nervous system. Incorporated in 2016 and headquartered in Kingston, Rhode Island, the company aims to treat conditions such as Alzheimer's disease, Huntington's disease, pain, and psychiatric disorders. MindImmune recognizes the critical interplay between the immune system and brain function, positioning itself at the forefront of research in this area. The company is also establishing collaborations with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to enhance its drug development efforts through access to academic resources within the expanding Rhode Island neuroscience ecosystem.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

NeuroVision Imaging LLC, established in 2010 and based in Sacramento, California, specializes in developing digital imaging and diagnostic solutions for Alzheimer's disease and eye care markets. The company's core focus is the development of diagnostic tests and biomarkers for the early detection and monitoring of amyloid pathology related to Alzheimer's disease. NeuroVision has pioneered a retinal imaging technology that uses low-cost, non-invasive eye imaging to measure retinal autofluorescence, aiming to assess the accumulation of amyloid-beta plaque in the brain. Additionally, the company offers data aggregation services, analysis, biostatistics, and machine learning algorithms to analyze large repositories of images and other biomarker data, furthering the understanding and prediction capabilities for neurodegenerative diseases. NeuroVision serves clients in the United States and internationally.

C. Light Technologies, Inc. is a neurotechnology and artificial intelligence company based in Berkeley, California, founded in 2014. The company specializes in developing advanced eye-tracking technology aimed at improving the monitoring and diagnosis of neurological health, particularly for conditions such as multiple sclerosis. C. Light's platform utilizes a highly accurate eye tracker, which is 150 times more precise than competing devices, along with machine learning algorithms. This innovative approach allows for the imaging of the retina to monitor neurological activity, providing clinicians with enhanced tools for assessing neurodegenerative diseases. By integrating sophisticated hardware and software, C. Light Technologies aims to optimize the diagnostic process for neurological disorders.

NeuroVision Imaging LLC, established in 2010 and based in Sacramento, California, specializes in developing digital imaging and diagnostic solutions for Alzheimer's disease and eye care markets. The company's core focus is the development of diagnostic tests and biomarkers for the early detection and monitoring of amyloid pathology related to Alzheimer's disease. NeuroVision has pioneered a retinal imaging technology that uses low-cost, non-invasive eye imaging to measure retinal autofluorescence, aiming to assess the accumulation of amyloid-beta plaque in the brain. Additionally, the company offers data aggregation services, analysis, biostatistics, and machine learning algorithms to analyze large repositories of images and other biomarker data, furthering the understanding and prediction capabilities for neurodegenerative diseases. NeuroVision serves clients in the United States and internationally.

Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.

C2N Diagnostics, LLC is a privately held company focused on the development of protein diagnostics and therapeutics targeting progressive neurodegeneration, particularly Alzheimer's disease. Founded in 2007 by Drs. David Holtzman and Randall Bateman from Washington University School of Medicine, along with LifeTech Research, the company operates from the Center for Emerging Technologies in St. Louis. C2N Diagnostics specializes in mass spectrometry-based techniques that allow for the precise identification, quantification, and monitoring of proteins and biomolecules associated with neurological disorders. By providing accurate and sensitive diagnostics, the company aims to enhance the detection and characterization of neurocognitive disorders, ultimately supporting improved patient care and treatment strategies.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

Biological Dynamics Inc. is a healthcare company based in San Diego, California, that specializes in developing a proprietary technology platform for the direct and selective capture of large necrotic particles from physiological solutions such as whole blood, serum, and plasma. This platform facilitates the detection of diseases, particularly cancers, in their earliest stages by enabling access to native-state biomarkers and nanoparticles for multiomics applications. The company offers various products and services, including the TR(ACE) Assay for monitoring treatment responses in cancer, tissue-based molecular and cfDNA liquid biopsy testing for personalized medicine, and a biomarkers program aimed at drug development for Alzheimer's disease. Additionally, Biological Dynamics provides clinical laboratory services, including molecular and next-generation sequencing, and supports applications in autoimmune diseases, transplant rejection, and traumatic brain injury. Founded in 2008, the company is dedicated to improving global health outcomes through innovative diagnostic solutions.

Vaccinex, Inc. is a clinical-stage biotechnology company based in Rochester, New York, that focuses on discovering and developing biotherapeutics for serious diseases with unmet medical needs. The company specializes in treatments for cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate, pepinemab, is currently in clinical development for various conditions, including non-small cell lung cancer, Huntington’s disease, and Alzheimer’s disease. Additionally, Vaccinex is developing VX5, a human antibody targeting CXCL13 for multiple sclerosis and other autoimmune disorders, and VX25, a bi-specific natural killer T cell stimulator aimed at cancer immunotherapy. Vaccinex employs a unique antibody discovery platform that facilitates the rapid selection of high-affinity human monoclonal antibodies. The company has also established a collaboration with Merck KGaA to explore the efficacy of pepinemab in combination with avelumab, a checkpoint inhibitor, for treating non-small cell lung cancer patients. Founded in 2001, Vaccinex is committed to advancing innovative treatments that address significant health challenges.

DiamiR is mission is to build a leading molecular diagnostics company focused on developing minimally invasive solutions for early detection and monitoring of brain and synaptic health conditions, including mild cognitive impairment and Alzheimer’s disease, to enable earlier intervention and better planning of care.

RetiSpec is a company focused on advancing early detection of Alzheimer’s Disease through its innovative non-invasive eye scanning technology. By employing AI-driven retinal imaging, RetiSpec's solution enables healthcare providers to identify neurodegenerative disease markers during a simple eye exam. This approach facilitates early diagnosis, allowing clinicians to intervene with emerging therapeutics before symptoms arise, thereby potentially impacting the progression of the disease. RetiSpec aims to make early detection accessible and affordable, contributing significantly to the management of Alzheimer's Disease.

AgeneBio is a neuroscience pharmaceutical company founded by Dr. Michela Gallagher in 2008, headquartered in Indianapolis. The company focuses on developing innovative therapeutics for neurological and psychiatric conditions that impact memory, with an initial emphasis on Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD). AgeneBio aims to prevent neurodegeneration and preserve or restore cognitive function for patients battling these conditions.

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. The company is focused on developing targeted therapies, and its clinical pipeline includes iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor also in Phase II trials for neurological diseases. Additionally, Oryzon is advancing ORY-3001, a selective LSD1 inhibitor in preclinical development aimed at treating non-oncological conditions, alongside other compounds at various stages of development. Founded in 2000, Oryzon leverages its epigenetic platform to identify biomarkers and therapeutic targets, fostering the creation of personalized medicine.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and halting neurodegeneration. The company's lead product candidate, ATH-1017, is a small molecule designed to penetrate the blood-brain barrier and acts as a hepatocyte growth factor/MET activator, currently undergoing various clinical trials for treating Alzheimer’s and Parkinson’s diseases. In addition to ATH-1017, Athira is developing several other candidates, including ATH-1019 for depression and ATH-1018 for peripheral neuropathy, which are in the preclinical stage. Founded in 2011 and initially known as M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its mission of advancing innovative therapies to improve the lives of individuals affected by brain disorders.

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. The company is focused on developing targeted therapies, and its clinical pipeline includes iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor also in Phase II trials for neurological diseases. Additionally, Oryzon is advancing ORY-3001, a selective LSD1 inhibitor in preclinical development aimed at treating non-oncological conditions, alongside other compounds at various stages of development. Founded in 2000, Oryzon leverages its epigenetic platform to identify biomarkers and therapeutic targets, fostering the creation of personalized medicine.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and halting neurodegeneration. The company's lead product candidate, ATH-1017, is a small molecule designed to penetrate the blood-brain barrier and acts as a hepatocyte growth factor/MET activator, currently undergoing various clinical trials for treating Alzheimer’s and Parkinson’s diseases. In addition to ATH-1017, Athira is developing several other candidates, including ATH-1019 for depression and ATH-1018 for peripheral neuropathy, which are in the preclinical stage. Founded in 2011 and initially known as M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its mission of advancing innovative therapies to improve the lives of individuals affected by brain disorders.

Tetra Therapeutics Inc. is a clinical-stage biotechnology company focused on developing pharmaceutical drugs that target phosphodiesterase (PDE) subtype inhibitors for various neurological and non-neurological disorders. The company is advancing BPN14770, a novel therapeutic agent designed to enhance synaptic actions in the brain's neurons, which is particularly relevant for conditions affecting memory and cognition, such as Alzheimer's disease, schizophrenia, and developmental disabilities. Tetra Therapeutics aims to create effective treatments for patients suffering from Alzheimer's, other dementias, traumatic brain injury, and psychiatric disorders. Founded in 2011 and based in Grand Rapids, Michigan, the company was previously known as Tetra Discovery Partners and rebranded in August 2019. Tetra Therapeutics has established a strategic collaboration with Shionogi & Co., Ltd., and as of July 2020, operates as a subsidiary of Shionogi.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. The company is focused on developing targeted therapies, and its clinical pipeline includes iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor also in Phase II trials for neurological diseases. Additionally, Oryzon is advancing ORY-3001, a selective LSD1 inhibitor in preclinical development aimed at treating non-oncological conditions, alongside other compounds at various stages of development. Founded in 2000, Oryzon leverages its epigenetic platform to identify biomarkers and therapeutic targets, fostering the creation of personalized medicine.

Metabolic Solutions Development Company, LLC is a biopharmaceutical firm focused on drug discovery and development aimed at addressing metabolic diseases associated with aging. Founded in 2006 and based in Kalamazoo, Michigan, the company is dedicated to investigating novel molecular targets for therapeutic intervention. It is developing a range of innovative oral therapeutics, including MSDC-0160 and MSDC-0602, to treat conditions such as type 2 diabetes, polycystic kidney disease, and neurodegenerative disorders like Alzheimer's and Parkinson's diseases. The company's approach involves creating non-thiazolidinedione insulin sensitizers that modulate mitochondrial function to improve metabolic control, addressing complications related to insulin resistance and other aspects of metabolic syndrome.

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. The company is focused on developing targeted therapies, and its clinical pipeline includes iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor also in Phase II trials for neurological diseases. Additionally, Oryzon is advancing ORY-3001, a selective LSD1 inhibitor in preclinical development aimed at treating non-oncological conditions, alongside other compounds at various stages of development. Founded in 2000, Oryzon leverages its epigenetic platform to identify biomarkers and therapeutic targets, fostering the creation of personalized medicine.

Cambridge Cognition Holdings Plc, established in 2012 and headquartered in Cambridge, UK, is a neuroscience technology company specializing in digital health solutions for cognitive assessment and research. The company offers a range of products, including CANTAB Recruit, an online patient recruitment platform for clinical trials; CANTAB Connect, a digital cognitive assessment tool for pharmaceutical clinical trials; and Cognition Kit, a digital health platform for data collection and patient engagement. Additionally, Cambridge Cognition provides expert consultancy services, such as neuroscience and technical consultancy, study design, data analysis, and management, to optimize clinical trials and cognitive research. The company's solutions are used in various therapeutic areas and stages of clinical trials, with a focus on high-need indications like Alzheimer's disease. Cambridge Cognition operates in the United States, the United Kingdom, the European Union, and internationally.

Metabolic Solutions Development Company, LLC is a biopharmaceutical firm focused on drug discovery and development aimed at addressing metabolic diseases associated with aging. Founded in 2006 and based in Kalamazoo, Michigan, the company is dedicated to investigating novel molecular targets for therapeutic intervention. It is developing a range of innovative oral therapeutics, including MSDC-0160 and MSDC-0602, to treat conditions such as type 2 diabetes, polycystic kidney disease, and neurodegenerative disorders like Alzheimer's and Parkinson's diseases. The company's approach involves creating non-thiazolidinedione insulin sensitizers that modulate mitochondrial function to improve metabolic control, addressing complications related to insulin resistance and other aspects of metabolic syndrome.

Life Molecular Imaging is a diagnostic center specializing in neuroimaging and cardiovascular imaging services. The company develops novel PET tracers aimed at advancing molecular imaging research, thereby enhancing the early detection and characterization of chronic and life-threatening diseases. Its offerings include research and development laboratories, a network of cyclotrons, radiopharmacies, and imaging facilities, which facilitate access for physicians, the pharmaceutical industry, and academic institutions to both established and innovative imaging agents. This comprehensive approach supports improved therapeutic outcomes and enhances the capabilities of clinical trials and routine clinical practice.